Achieving Cross-Functional Supplier Integration: A Case-Study Analysis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Achieving Cross-Functional Supplier Integration: A Case-Study Analysis
The article examines a cross-functional supplier integration model to facilitate project management.


Pharmaceutical Technology
Volume 35, pp. s54-s58


MICHAEL HITOSHI / GETTY IMAGES
Effective project management is an ongoing task for sponsor companies and contract-service providers. For a given project, a pharmaceutical company may be tasked with managing the timelines and deliverables from several vendors engaged in disparate functions, such as process development and manufacturing of active pharmaceutical ingredients (APIs), formulation development, and finished drug-product manufacturing. The success of each of these functions is interrelated. The availability and quality of APIs, for example, directly affects the timeline for delivering a quality formulation and finished drug product. Cross-functional supplier integration is becoming more important as pharmaceutical companies respond to an increasingly cost-competitive environment and seek ways to optimize their external development and manufacturing functions .

"The global pharmaceutical industry is undergoing a period of rapid change," explains Brian Scanlan, CEO and president of Cambridge Major Laboratories, a contract API manufacturer. "Big Pharma is divesting assets and taking on a more virtual model shared by the majority of the emerging pharma sector. With this change also comes opportunity—an opportunity to set a new model for API and drug-development sourcing," he says. This new model is predicated on improved cross-functional supplier integration to create a so-called "virtual one stop-shop," which relies on increased communication and project management among suppliers. "This virtual one stop-shop has distinct advantages to the traditional one-stop model. Specifically, that individual best-in-class suppliers can come together to achieve the common goal of getting the client's molecule to market faster," he explains.

Cambridge Major Laboratories is a participant in such a model through an alliance established with three other partners: Xcelience, a contract provider of formulation development and finished drug-product manufacturing; Micron Technologies, a provider of cGMP micronizing and milling; and Beckloff Associates, a scientific and regulatory consulting firm and subsidiary of Cardinal Health. Under the model, named the Chemistry Playbook, each company is independent and responsible for its own activities and project management, but a prospective sponsor company, if it wishes, can use the complementary service offerings of all or some of the partners. The model brings together the functional expertise of each alliance member but with enhanced cooperation, such as by providing a single point of contact among all the contract-service providers for the sponsor company and offering integrated commercial and billing processes.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here